BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid. 2014;24:1256-1266. [PMID: 24798740 DOI: 10.1089/thy.2013.0610] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Cadena-ullauri S, Paz-cruz E, Tamayo-trujillo R, Guevara-ramírez P, Ruiz-pozo V, Solis-pazmino P, Garcia C, Godoy R, Lincango-naranjo E, Zambrano AK. Identification of KIT and BRAF mutations in thyroid tissue using next-generation sequencing in an Ecuadorian patient: A case report. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1101530] [Reference Citation Analysis]
2 Zhang X, Ze Y, Sang J, Shi X, Bi Y, Shen S, Zhang X, Zhu D. Risk factors and diagnostic prediction models for papillary thyroid carcinoma. Front Endocrinol 2022;13:938008. [DOI: 10.3389/fendo.2022.938008] [Reference Citation Analysis]
3 Osborne D, Choudhary R, Vyas A, Kampa P, Abbas LF, Chigurupati HD, Alfonso M. Hashimoto’s Thyroiditis Effects on Papillary Thyroid Carcinoma Outcomes: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.28054] [Reference Citation Analysis]
4 Vodopivec DM, Hu MI. RET kinase inhibitors for RET-altered thyroid cancers. Ther Adv Med Oncol 2022;14:17588359221101691. [PMID: 35756966 DOI: 10.1177/17588359221101691] [Reference Citation Analysis]
5 Nacchio M, Pisapia P, Pepe F, Russo G, Vigliar E, Porcelli T, Luongo C, Iaccarino A, Pagni F, Salvatore D, Troncone G, Malapelle U, Bellevicine C. Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. Expert Rev Endocrinol Metab 2022;17:167-78. [PMID: 35404189 DOI: 10.1080/17446651.2022.2060819] [Reference Citation Analysis]
6 Luo Y, Chen R, Ning Z, Fu N, Xie M. Identification of a Four-Gene Signature for Determining the Prognosis of Papillary Thyroid Carcinoma by Integrated Bioinformatics Analysis. IJGM 2022;Volume 15:1147-60. [DOI: 10.2147/ijgm.s346058] [Reference Citation Analysis]
7 Yao L, Wang Y, Mohankumar S. Bioinformatic Analysis of the Effect of the Sirtuin Family on Differentiated Thyroid Carcinoma. BioMed Research International 2022;2022:1-15. [DOI: 10.1155/2022/5794118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Ramkumar S, Sivanandham S. The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma. Cureus. [DOI: 10.7759/cureus.20339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Murugan AK, Qasem E, Al-Hindi H, Alzahrani AS. Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers. Mol Clin Oncol 2021;15:210. [PMID: 34462665 DOI: 10.3892/mco.2021.2373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Rogounovitch TI, Mankovskaya SV, Fridman MV, Leonova TA, Kondratovitch VA, Konoplya NE, Yamashita S, Mitsutake N, Saenko VA. Major Oncogenic Drivers and Their Clinicopathological Correlations in Sporadic Childhood Papillary Thyroid Carcinoma in Belarus. Cancers (Basel) 2021;13:3374. [PMID: 34282777 DOI: 10.3390/cancers13133374] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Singh A, Ham J, Po JW, Niles N, Roberts T, Lee CS. The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy. Cells 2021;10:1082. [PMID: 34062862 DOI: 10.3390/cells10051082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Lu YL, Huang YT, Wu MH, Chou TC, J Wong R, Lin SF. Efficacy of adavosertib therapy against anaplastic thyroid cancer. Endocr Relat Cancer 2021;28:311-24. [PMID: 33769310 DOI: 10.1530/ERC-21-0001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ma Y, Yin S, Liu XF, Hu J, Cai N, Zhang XB, Fu L, Cao XC, Yu Y. Comprehensive Analysis of the Functions and Prognostic Value of RNA-Binding Proteins in Thyroid Cancer. Front Oncol 2021;11:625007. [PMID: 33816259 DOI: 10.3389/fonc.2021.625007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 He J, Zhou M, Yin J, Wan J, Chu J, Jia J, Sheng J, Wang C, Yin H, He F. METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8-mediated neutrophil infiltration. Mol Ther 2021;29:1821-37. [PMID: 33484966 DOI: 10.1016/j.ymthe.2021.01.019] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 18.5] [Reference Citation Analysis]
15 Zhang R, Dong L, Yu J. Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors. Front Oncol 2020;10:544579. [PMID: 33520689 DOI: 10.3389/fonc.2020.544579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Rashid FA, Munkhdelger J, Fukuoka J, Bychkov A. Prevalence of BRAFV600E mutation in Asian series of papillary thyroid carcinoma-a contemporary systematic review. Gland Surg 2020;9:1878-900. [PMID: 33224863 DOI: 10.21037/gs-20-430] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
17 Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, Yasumatsu R, Oda Y. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas. Hum Pathol 2020;106:82-92. [PMID: 32980422 DOI: 10.1016/j.humpath.2020.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
18 Cho YY, Park SY, Shin JH, Oh YL, Choe JH, Kim JH, Kim JS, Yim HS, Kim YL, Ki CS, Kim TH, Chung JH, Kim SW. Highly Sensitive and Specific Molecular Test for Mutations in the Diagnosis of Thyroid Nodules: A Prospective Study of BRAF-Prevalent Population. Int J Mol Sci 2020;21:E5629. [PMID: 32781560 DOI: 10.3390/ijms21165629] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Al-Jundi M, Thakur S, Gubbi S, Klubo-Gwiezdzinska J. Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review. Cancers (Basel) 2020;12:E2104. [PMID: 32751138 DOI: 10.3390/cancers12082104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 9.7] [Reference Citation Analysis]
20 Shi C, Cao J, Shi T, Liang M, Ding C, Lv Y, Zhang W, Li C, Gao W, Wu G, Man J. BRAFV600E mutation, BRAF-activated long non-coding RNA and miR-9 expression in papillary thyroid carcinoma, and their association with clinicopathological features. World J Surg Oncol 2020;18:145. [PMID: 32593310 DOI: 10.1186/s12957-020-01923-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Wang X, Fu X, Zhang J, Xiong C, Zhang S, Lv Y. Identification and validation of m6A RNA methylation regulators with clinical prognostic value in Papillary thyroid cancer. Cancer Cell Int 2020;20:203. [PMID: 32514248 DOI: 10.1186/s12935-020-01283-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 7.7] [Reference Citation Analysis]
22 Li M, Jia H, Qian Q, Wen P, Chen C, Hua Y, Wang K, Zhang W, Shi F. Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population. Diagn Pathol 2020;15:49. [PMID: 32393293 DOI: 10.1186/s13000-020-00962-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
23 Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid 2020;30:1288-96. [PMID: 32216548 DOI: 10.1089/thy.2019.0514] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
24 Al-Salam S, Sharma C, Afandi B, Al Dahmani K, Al-Zahrani AS, Al Shamsi A, Al Kaabi J. BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates. PLoS One 2020;15:e0231341. [PMID: 32315324 DOI: 10.1371/journal.pone.0231341] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
25 Suster D, Michal M, Nishino M, Piana S, Bongiovanni M, Blatnik O, Hájková V, Ptáková N, Michal M, Suster S. Papillary thyroid carcinoma with prominent myofibroblastic stromal component: clinicopathologic, immunohistochemical and next-generation sequencing study of seven cases. Mod Pathol 2020;33:1702-11. [PMID: 32291398 DOI: 10.1038/s41379-020-0539-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
26 Prete A, Borges de Souza P, Censi S, Muzza M, Nucci N, Sponziello M. Update on Fundamental Mechanisms of Thyroid Cancer. Front Endocrinol (Lausanne) 2020;11:102. [PMID: 32231639 DOI: 10.3389/fendo.2020.00102] [Cited by in Crossref: 78] [Cited by in F6Publishing: 93] [Article Influence: 26.0] [Reference Citation Analysis]
27 Subbiah V, Yang D, Velcheti V, Drilon A, Meric-Bernstam F. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol 2020;38:1209-21. [PMID: 32083997 DOI: 10.1200/JCO.19.02551] [Cited by in Crossref: 87] [Cited by in F6Publishing: 94] [Article Influence: 29.0] [Reference Citation Analysis]
28 Kocsis-Deák B, Árvai K, Balla B, Tóbiás B, Kohánka A, Járay B, Horányi J, Podani J, Takács I, Putz Z, Kósa J, Lakatos P. Targeted Mutational Profiling and a Powerful Risk Score as Additional Tools for the Diagnosis of Papillary Thyroid Cancer. Pathol Oncol Res 2020;26:101-8. [PMID: 31758407 DOI: 10.1007/s12253-019-00772-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ze Y, Zhang X, Shao F, Zhu L, Shen S, Zhu D, Bi Y. Active surveillance of low-risk papillary thyroid carcinoma: a promising strategy requiring additional evidence. J Cancer Res Clin Oncol 2019;145:2751-9. [PMID: 31571010 DOI: 10.1007/s00432-019-03021-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
30 Pekova B, Dvorakova S, Sykorova V, Vacinova G, Vaclavikova E, Moravcova J, Katra R, Vlcek P, Sykorova P, Kodetova D, Vcelak J, Bendlova B. Somatic genetic alterations in a large cohort of pediatric thyroid nodules. Endocr Connect 2019;8:796-805. [PMID: 31085772 DOI: 10.1530/EC-19-0069] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
31 Zhu G, Deng Y, Pan L, Ouyang W, Feng H, Wu J, Chen P, Wang J, Chen Y, Luo J. Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy. Endocr Connect 2019;8:754-63. [PMID: 31071680 DOI: 10.1530/EC-19-0045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
32 Song Y, Fu LJ, Li HT, Qiu XG. Evaluation of MEDAG gene expression in papillary thyroid microcarcinoma: associations with histological features, regional lymph node metastasis and prognosis. Sci Rep 2019;9:5800. [PMID: 30967566 DOI: 10.1038/s41598-019-41701-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Martínez JRW, Vargas-salas S, Gamboa SU, Muñoz E, Domínguez JM, León A, Droppelmann N, Solar A, Zafereo M, Holsinger FC, González HE. The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer. HORM CANC 2019;10:97-106. [DOI: 10.1007/s12672-019-0359-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Ochoa S, Martínez-Pérez E, Zea DJ, Molina-Vila MA, Marino-Buslje C. Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches. Hum Mutat 2019;40:413-25. [PMID: 30629309 DOI: 10.1002/humu.23705] [Reference Citation Analysis]
35 Jiang W, Wei HY, Zhang HY, Zhuo QL. Value of contrast-enhanced ultrasound combined with elastography in evaluating cervical lymph node metastasis in papillary thyroid carcinoma. World J Clin Cases 2019; 7(1): 49-57 [PMID: 30637252 DOI: 10.12998/wjcc.v7.i1.49] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
36 Ahmad F, Nathani R, Venkat J, Bharda A, Vanere V, Bhatia S, Das BR. Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of aggressive disease. Experimental and Molecular Pathology 2018;105:380-6. [DOI: 10.1016/j.yexmp.2018.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
37 Zarkesh M, Zadeh-Vakili A, Azizi F, Foroughi F, Akhavan MM, Hedayati M. Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes. Mol Diagn Ther 2018;22:41-56. [PMID: 28986854 DOI: 10.1007/s40291-017-0303-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
38 Pstrąg N, Ziemnicka K, Bluyssen H, Wesoły J. Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates. Mol Cancer 2018;17:116. [PMID: 30089490 DOI: 10.1186/s12943-018-0866-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
39 Kor Y, Zou M, Al-Rijjal RA, Monies D, Meyer BF, Shi Y. Phenotype heterogeneity of congenital adrenal hyperplasia due to genetic mosaicism and concomitant nephrogenic diabetes insipidus in a sibling. BMC Med Genet 2018;19:115. [PMID: 29996815 DOI: 10.1186/s12881-018-0629-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
40 He H, Li W, Yan P, Bundschuh R, Killian JA, Labanowska J, Brock P, Shen R, Heerema NA, de la Chapelle A. Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. Thyroid 2018;28:748-54. [PMID: 29768105 DOI: 10.1089/thy.2017.0258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
41 Huang L, Wang X, Huang X, Gui H, Li Y, Chen Q, Liu D, Liu L. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018;15:4269-77. [PMID: 29541194 DOI: 10.3892/ol.2018.7873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Dou R, Zhang L, Lu T, Liu D, Mei F, Huang J, Qian L. Identification of a novel HRAS variant and its association with papillary thyroid carcinoma. Oncol Lett 2018;15:4511-6. [PMID: 29556290 DOI: 10.3892/ol.2018.7818] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
43 George N, Agarwal A, Kumari N, Agarwal S, Krisnani N, Gupta SK. Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India. Indian J Endocrinol Metab 2018;22:505-10. [PMID: 30148098 DOI: 10.4103/ijem.IJEM_441_17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
44 Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 2016;7:30907-23. [PMID: 27127178 DOI: 10.18632/oncotarget.9023] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
45 Su X, Li Z, He C, Chen W, Fu X, Yang A. Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget 2016;7:16716-30. [PMID: 26918339 DOI: 10.18632/oncotarget.7574] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 5.5] [Reference Citation Analysis]
46 Vuong HG, Altibi AM, Duong UN, Ngo HT, Pham TQ, Tran HM, Oishi N, Mochizuki K, Nakazawa T, Hassell L, Katoh R, Kondo T. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations—a meta-analysis. Tumour Biol 2017;39:101042831771391. [DOI: 10.1177/1010428317713913] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
47 Chen L, Zhao L, Ding M, Yang M, Yang W, Cui G, Shan B. Higher expression level of tyrosine kinase-like orphan receptor 2 and Wnt member 5a in papillary thyroid carcinoma is associated with poor prognosis. Oncol Lett 2017;14:5966-72. [PMID: 29113233 DOI: 10.3892/ol.2017.6989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Ochoa S, Martínez-pérez E, Zea DJ, Molina-vila MA, Marino-buslje C. Co-mutation and exclusion analysis in human tumors, a means for cancer biology studies and treatment design.. [DOI: 10.1101/182501] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
49 Cheng Q, Li X, Acharya CR, Hyslop T, Sosa JA. A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors. Oncotarget 2017;8:16690-703. [PMID: 28187428 DOI: 10.18632/oncotarget.15128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
50 Yu K, Wang T, Li Y, Wang C, Wang X, Zhang M, Xie Y, Li S, An Z, Ye T. Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro. Biomedicine & Pharmacotherapy 2017;92:403-11. [DOI: 10.1016/j.biopha.2017.05.097] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
51 Rendl G, Rodrigues M, Schweighofer-Zwink G, Hutter J, Hittmair A, Zellinger B, Hauser-Kronberger C, Pirich C. Clinicopathological characteristics of thyroid cancer in the federal state of Salzburg. Wien Klin Wochenschr 2017;129:540-4. [PMID: 28493027 DOI: 10.1007/s00508-017-1207-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Franceschi S, Lessi F, Panebianco F, Tantillo E, La Ferla M, Menicagli M, Aretini P, Apollo A, Naccarato AG, Marchetti I, Mazzanti CM. Loss of c-KIT expression in thyroid cancer cells. PLoS One 2017;12:e0173913. [PMID: 28301608 DOI: 10.1371/journal.pone.0173913] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
53 Vuong HG, Duong UN, Altibi AM, Ngo HT, Pham TQ, Tran HM, Gandolfi G, Hassell L. A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma. Endocr Connect 2017;6:R8-R17. [PMID: 28219937 DOI: 10.1530/EC-17-0010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 8.5] [Reference Citation Analysis]
54 Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. Cancer Res Treat 2017;49:906-14. [PMID: 28052655 DOI: 10.4143/crt.2016.424] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
55 Ning L, Rao W, Yu Y, Liu X, Pan Y, Ma Y, Liu R, Zhang S, Sun H, Yu Q. Association between the KRAS Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population. J Cancer 2016;7:2420-6. [PMID: 27994680 DOI: 10.7150/jca.16507] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
56 Gertz RJ, Nikiforov Y, Rehrauer W, McDaniel L, Lloyd RV. Mutation in BRAF and Other Members of the MAPK Pathway in Papillary Thyroid Carcinoma in the Pediatric Population. Arch Pathol Lab Med 2016;140:134-9. [PMID: 26910217 DOI: 10.5858/arpa.2014-0612-OA] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
57 Song HM, Song JL, Li DF, Hua KY, Zhao BK, Fang L. Inhibition of FOXO1 by small interfering RNA enhances proliferation and inhibits apoptosis of papillary thyroid carcinoma cells via Akt/FOXO1/Bim pathway. Onco Targets Ther 2015;8:3565-73. [PMID: 26664140 DOI: 10.2147/OTT.S95395] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
58 Zou M, Baitei EY, Al-Rijjal RA, Parhar RS, Al-Mohanna FA, Kimura S, Pritchard C, Binessa HA, Alzahrani AS, Al-Khalaf HH, Hawwari A, Akhtar M, Assiri AM, Meyer BF, Shi Y. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. Oncogene 2016;35:1909-18. [PMID: 26477313 DOI: 10.1038/onc.2015.253] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
59 Bastos AU, Oler G, Nozima BHN, Moysés RA, Cerutti JM. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. European Journal of Endocrinology 2015;173:525-40. [DOI: 10.1530/eje-15-0254] [Cited by in Crossref: 38] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
60 Yu M, Wang J, Ma D, Chen S, Lin X, Fang Q, Zhe N. HO-1, RET and PML as possible markers for risk stratification of acute myelocytic leukemia and prognostic evaluation. Oncol Lett 2015;10:3137-44. [PMID: 26722301 DOI: 10.3892/ol.2015.3644] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
61 Tobiás B, Halászlaki C, Balla B, Kósa JP, Árvai K, Horváth P, Takács I, Nagy Z, Horváth E, Horányi J, Járay B, Székely E, Székely T, Győri G, Putz Z, Dank M, Valkusz Z, Vasas B, Iványi B, Lakatos P. Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer. Pathol Oncol Res 2016;22:27-33. [PMID: 26259532 DOI: 10.1007/s12253-015-9969-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 White PT, Cohen MS. The discovery and development of sorafenib for the treatment of thyroid cancer. Expert Opin Drug Discov 2015;10:427-39. [PMID: 25662396 DOI: 10.1517/17460441.2015.1006194] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
63 Jin H, Liang Y, Wang X, Zhu J, Sun R, Chen P, Nie X, Gao L, Zhang L. Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer. Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0221-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]